Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis b-haemophilus influenzae b conjugate combined vaccine in healthy 2-, 4-, and 6-month-old argentinean infants

Pediatric Infectious Disease Journal

Volumn 30, Issue 6, 2011, Pages

  Tregnaghi, Miguel W ^a   Zambrano, Betzana ^b   Santos Lima, Eduardo ^c  

^a Centro de Desarrollo de Proyectos Avanzados Cordoba   (Argentina)

^b Sanofi Pasteur   (Uruguay)

^c SANOFI PASTEUR   (France)

Author keywords

Acellular pertussis; Combination; Diphtheria; Haemophilus influenzae type b; Hep B; Hexavalent; Immunization; Inactivated poliovirus; Pediatric; Tetanus; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIGEN; PENTAXIM; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANOREXIA; ANTIBODY TITER; ARGENTINA; ARTICLE; CONTROLLED STUDY; CRYING; DIARRHEA; DRUG SAFETY; FEVER; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFLUENZA B; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; NEWBORN; NONHUMAN; PERTUSSIS; PHASE 2 CLINICAL TRIAL; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; SIDE EFFECT; SOMNOLENCE; TETANUS; VACCINATION; VOMITING;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ARGENTINA; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; VACCINES, CONJUGATE;

EID: 79958020877     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318212eb80     Document Type: Article

References (38)

1. Edwards KM, Decker MD. Combination vaccines: hopes and challenges. Pediatr Infect Dis J. 1994;13:345-347.
2. Obaro SK, Palmer A. Vaccines for children: policies, politics and poverty. Vaccine. 2003;21:1423-1431.
3. Ball TM, Serwint JR. Missed opportunities for vaccination and the delivery of preventive care. Arch Pediatr Adolesc Med. 1996;150:858-861.
4. Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J. 2001;20(suppl 11):S10-S18.
5. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(suppl 1):S6-S12.
6. Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26:496-500.
7. Reis EC, Roth EK, Syphan JL, et al. Effective pain reduction for multiple immunization injections in young infants. Arch Pediatr Adolesc Med. 2003;157:1115-1120.
8. Bar-On ES, Goldberg E, Fraser A, et al. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev. 2009:CD005530.
9. Decker M, Bogaerts H, Edwards K. Combination vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders Co; 2008:1069-1101.
10. Edwards KM, Decker MD. Combination vaccines. Infect Dis Clin North Am. 2001;15:209-230.
11. Combination vaccines for childhood immunization. MMWR Recomm Rep. 1999;48(RR-5):1-14.
12. Gustafsson L, Hessel L, Storsaeter J, et al. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics. 2006;118:978-984.
13. Langue J, Matisse N, Pacoret P, et al. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. Vaccine. 2004;22:1406-1414.
14. Mallet E, Matisse N, Mathieu N, et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine. 2004;22:1415-1422.
15. Zepp F, Schmitt HJ, Cleerbout J, et al. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines. 2009;8:663-678.
16. Zinke M, Kappes R, Kindler K, et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin. 2009;5:592-598.
17. Edwards K, Decker M. Pertussis vaccines. In: Plotkin S, Orenstein W, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders Co; 2008:467-517.
18. Capeding MR, Cadorna-Carlos J, Book-Montellano M, et al. Immunogenicity and safety of a DTaP-IPV//PRP˜T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bull World Health Organ. 2008;86:443-451.
19. Carlsson RM, Claesson BA, Selstam U, et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J. 1998;17:1026-1033.
20. Carlsson RM, Claesson BA, Fagerlund E, et al. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J. 2002;21:535-541.
21. Kanra G, Silier T, Yurdakok K, et al. Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life. Vaccine. 1999;18:947-954.
22. Lagos R, Kotloff K, Hoffenbach A, et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four-and six-month-old Chilean infants. Pediatr Infect Dis J. 1998;17:294-304.
23. Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Hum Vaccin. 2008;4:328-340.
24. Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine. 2008;26:4978-4983.
25. Tregnaghi MW, Voelker R, Santos-Lima E, et al. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine. 2010;28:3595-3601.
26. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873-890.
27. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9:1447-1454.
28. Pasetti M, Eriksson P, Ferrero F, et al. Serum antibodies to diphtheria-tetanus-pertussis vaccine components in Argentine children. Infection. 1997;25:339-345.
29. Halsey NA, Moulton LH, O'Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics. 1999;103(6 Pt 1):1243-1247.
30. Tregnaghi M, Ussher J, Baudagna AM, et al. Comparison of two recombinant hepatitis B vaccines and their interchangeability in Argentine infants. Rev Panam Salud Publica. 2004;15:35-40.
31. Gall SA. Maternal immunization to protect the mother and neonate. Expert Rev Vaccines. 2005;4:813-818.
32. Koenig MA, Roy NC, McElrath T, et al. Duration of protective immunity conferred by maternal tetanus toxoid immunization: further evidence from Matlab, Bangladesh. Am J Public Health. 1998;88:903-907.
33. Vitek C, Wharton M. Diphtheria toxoid. In: Plotkin S, Orenstein W, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders Co; 2008:139-156.
34. World Health Organization. Pertussis position paper. Weekly Epidemiol Rec. 2005;80:31.
35. Aristegui J, Dal Re R, Diez-Delgado J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine. 2003;21:3593-3600.
36. Halperin SA, Tapiero B, Diaz-Mitoma F, et al. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Vaccine. 2009;27:2540-2547.
37. Nolan T, Altmann A, Skeljo M, et al. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine. 2004;23:14-20.
38. Tichmann I, Preidel H, Grunert D, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine. 2005;23:3272-3279.